Bispecific antibodies may also provide an effective treatment for solid tumours non-respondent to available monoclonal antibodies such as the commercial anti-epidermal growth factor receptor (EGFR) antibody cetuximab that shows no efficacy as a monotherapy in BRAF-mutated colorectal cancer24. Here, EGFR is linked to medical procedure.